CLiMB Study Published in the Journal of Hepatology
Our landmark liver cancer detection study is now peer-reviewed and published.
Read More
HelioLiver™ LDT · A Simple Blood Test for Liver Cancer
Saving Lives by Detecting Cancer Early
At Helio, we're on a mission to save lives. With just a simple blood test, we empower more people to check for cancer early and often, when it is most treatable, so everyone has the best chance to beat it.
Validated in the CLiMB trial
Published in the Journal of Hepatology
90%
survival when cancer is
caught at an early stage
caught at an early stage
4×
more Stage I cancers
detected vs. ultrasound
detected vs. ultrasound
HelioLiver™ · A simple blood test for liver cancer
HelioLiver™ LDT
A simple blood test for the early detection of liver cancer (HCC), now available through Quest Diagnostics.
Our Mission
Finding Cancer Early Is the Key to Defeating It
For the majority of cancers, 90% of people survive if their cancer is detected at an early stage. But many of today's diagnostics are inconvenient, expensive, and poor predictors of early-stage cancer.
Now with Helio, finding cancer early is as simple as a blood draw. We focus our work on early detection, when treatment is most effective, and the chances of beating cancer are highest.
5-Year Survival by Stage at Detection
Majority of cancers
Detected early stage
90%
Detected late stage
21%
4× higher
Catching cancer early can quadruple the chance of survival. Source: SEER Database.
Our First Commercial Test
Detect Liver Cancer Earlier Than Ever Before
HelioLiver™ LDT is the first test built on the Helio platform, and it's available for clinical use today. In the CLiMB trial, this groundbreaking blood test detected Stage I liver cancer four times more often than ultrasound, the current standard of care. By reading cell-free DNA methylation alongside protein tumour markers and your clinical history, HelioLiver finds hepatocellular carcinoma (HCC) earlier, when it's smaller, more treatable, and curative options like surgery and transplant are still on the table.
40% vs 10%
Stage I HCC detection, HelioLiver vs ultrasound
29% vs 0%
sensitivity for lesions under 2 cm
10–14 days
average turnaround time
A simple, affordable blood test that reimagines how we find and fight liver cancer, integrating seamlessly with in-office patient care.
Validated in the CLiMB trial and published in the Journal of Hepatology, May 2026. Now available to order through Quest Diagnostics.
The Helio Platform
One Platform. A Smarter Way to Detect Cancer.
HelioLiver is the first test built on Helio's broader AI-powered platform, which reads cell-free DNA methylation patterns to detect cancer early, and is designed to do more than detect a single disease.
Early Detection
We read proprietary methylation patterns in cell-free DNA that can reveal cancer as early as Stage I from a simple blood draw, when treatment works best.
Disease Monitoring
Beyond detection, our platform is designed to monitor minimal residual disease, helping clinicians track response and guide decisions over time.
Powered by AI
Machine learning turns complex biomarker data into clear, reliable answers, built on proprietary, patented science developed over nearly a decade.
The Science & Proof
Backed by Nearly a Decade of Peer-Reviewed Science
Since 2016, Helio Genomics has pioneered the use of DNA methylation for early cancer detection, with foundational research published in some of the world's most respected scientific journals.
2016
Founded with a proprietary, patented methylation profile of novel cancer biomarkers
2017
Early methylation detection research was published in Nature Materials and PNAS
2021
An AI and machine learning detection method was published in Nature Communications
2026
CLiMB trial results published in the Journal of Hepatology
Why It Matters
Timing Matters. Early Detection Can Lead to Better Outcomes.
Fewer than half of all liver cancers in the US are diagnosed at an early stage, while the disease is still localised. Early detection significantly improves outcomes, allowing for a higher survival rate and opening the door to potentially curative treatment options, such as surgery and transplant.
Five-year relative survival falls from localised (early-stage) to distant (advanced-stage) liver cancer · SEER Database
Partners & Recognition
We Collaborate with Leaders in Clinical Care
Bringing this groundbreaking work to patients takes partnership. Helio Genomics collaborates with leaders in clinical care and technology to expand access to early testing, including clinical availability through Quest Diagnostics, one of the largest diagnostic networks in the United States, and a strategic commercial partnership with Syneos Health. Helio Genomics also participates in the Rural Health Transformation Collaborative, a Microsoft-co-chaired initiative expanding access to earlier liver cancer detection in underserved communities.
Rural Health Transformation CollaborativeCo-chaired by Microsoft
For Every Audience
Find Your Path
For Healthcare Providers
Bring earlier cancer detection into your practice with a simple blood draw.
For ProvidersFor Patients
If you are at higher risk for liver cancer, learn how a simple blood test could help find it earlier.
For PatientsFor Investors & Partners
Explore the platform, the science, and the momentum behind Helio Genomics.
Investor Relations
News & Updates
Latest from Helio Genomics
Helio Genomics Partners with Syneos Health
A strategic commercial partnership to accelerate national adoption of HelioLiver.
Read MoreHelio Genomics CEO on the Future of Early Cancer Detection
Dr. Bharat Tewarie on where the company and the field are headed.
Watch the InterviewTake the First Step Toward Early Detection
From our first test to our next, Helio Genomics is building the future of early cancer detection, one blood draw at a time. Take the first step toward early detection and better outcomes with HelioLiver LDT.